Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
64 hedge funds and large institutions have $96.1M invested in Soleno Therapeutics in 2020 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 16 increasing their positions, 4 reducing their positions, and 10 closing their positions.
310% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 10
300% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 4
98% more capital invested
Capital invested by funds: $48.5M → $96.1M (+$47.6M)
94% more funds holding
Funds holding: 33 → 64 (+31)
56% more call options, than puts
Call options by funds: $4.74M | Put options by funds: $3.04M
11.33% more ownership
Funds ownership: 46.46% → 57.79% (+11%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$9.63M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$9.1M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$8.78M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$7.3M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$6.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.81M |
| 2 |
6CM
683 Capital Management
New York
|
-$952K |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$579K |
| 4 |
Millennium Management
New York
|
-$272K |
| 5 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$231K |
SLNO Hedge Fund Activity: Q2 2020 in Review
64 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2020, worth a combined $96.1M — up 98% from $48.5M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new SLNO positions and 10 closed out — a net gain of 31 holders — while 16 added to existing stakes and 4 trimmed.
The largest buyer was Abingworth, adding an estimated $9.63M. The largest seller was Vivo Capital, exiting entirely with an estimated $4.81M sold.
- 64 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2020, up from 33 in Q1 2020.
- Funds reported $96.1M of Soleno Therapeutics stock for Q2 2020, up 98% quarter-over-quarter.
- 41 funds opened new Soleno Therapeutics positions in Q2 2020 and 10 closed out, a net change of +31 holders.
- The largest Soleno Therapeutics buyer in Q2 2020 was Abingworth, an estimated $9.63M added.
- The largest Soleno Therapeutics seller in Q2 2020 was Vivo Capital, an estimated $4.81M sold.
Based on aggregated 13F filings for Q2 2020.